A Simple Anti-body for the CD47 Protein Showing Real Promise in Cancer Cure

I ran across two very interesting articles this morning. The first summarizes research being done at Stanford University’s Institute of Stem Cell Biology and Regenerative Medicine and the Ludwig Center for Cancer Stem Cell Research.

Invadopodium extension by a cancer cell

Invadopodium extension by a cancer cell (Photo credit: TheJCB)

In short, researchers have found the the CD47 protein acts to protect cancer cells from the body’s natural immune systems defenses. They have developed an antibody that “unmasks” the protective cloak the CD47 protein provides the cancer cells.

The result is that the body’s natural immense system recognizes cancer cells and deals with them naturally.

You reach the entire article at Health Newsrack.

Stanford University Institute for Stem Cell Biology and Regenerative Medicine.

This looks like a very interesting technology to watch.

Be sure and follow our 2012 Prostate Cancer Pony Express riders at See the Prostate Cancer Pony Express riders in real time at http://bit.ly/ProstateCancerPonyExpressLive.

Advertisements

About The Success Architect®

Founder and CEO of The Success Foundry | Best Selling Author | Speaker | Senior Fellow @ the Center for the Digital Future USC Annenberg School |Business Coach Founder, CEO of TSG Inc | Founder and Partner of InterSpaceLA | Thought Partner | LinkedIn Trainer and Coach | Founder of Pony Express Riders | Motorcycle Rider | Bicycle Racer | USA Cycling Coach | Retired career Army officer | Prostate Cancer Advocate | Founder and CEO of Prostate Cancer Awareness Project, Inc. | Find me at LinkedIn.com/in/robertwarrenhess.
This entry was posted in Diagnostic tools and tagged . Bookmark the permalink.

2 Responses to A Simple Anti-body for the CD47 Protein Showing Real Promise in Cancer Cure

  1. Pingback: Prostate Cancer Pony Express Rides On! | Cars for Prostate Cancer

  2. Pingback: Stanford: Antibody offers hope against cancers - Stem Cell News | Stem Cell News

Comments are closed.